Business Wire

Mary Kay Inc. Joins Forces with the Equal Rights Trust to Pioneer Research on Gender Inequality in Algorithms and Artificial Intelligence

4.10.2021 11:00:00 EEST | Business Wire | Press release

Share

Mary Kay Inc., a global leader in women’s empowerment, today announced a partnership with the Equal Rights Trust (ERT), an organization whose mission is to eliminate all forms of discrimination and ensure everyone can participate in society on an equal basis. Established in 2007, the Trust works in partnership to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. will help ERT jumpstart an innovative field of research on artificial intelligence and algorithms through a gender-based lens.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005308/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Equal Rights Trust logo (Graphic: Mary Kay Inc.)

“As a company founded on the mission to enrich the lives of women everywhere, Mary Kay is constantly on the lookout for organizations we can partner with to make an impact for gender equality globally,” said Julia Simon, Chief Legal Officer and Chief Diversity Officer of Mary Kay Inc. “We’re excited to support Equal Rights Trust on their work to help advance equality by design and beyond forge a way forward to collaborations with the private sector. Our work with ERT is specifically focused on framing the new landscape of artificial intelligence and gender equality, a growing concern in the digital age.”

Mary Kay’s support to the ERT will pioneer a new field of research on the discriminatory impact of algorithmic systems. ERT has developed and promoted models of equality impact assessment, advocating an “equality by design” approach in public and private decision making as a means to ensure non-discrimination and equality of participation. An immediate priority is to launch an initiative to establish and address the emerging discriminatory impacts of algorithmic decision-making, specifically as it relates to gender.

“The use of algorithms and artificial intelligence is spreading,” said Ariane Adam, Deputy Director of the Equal Rights Trust. “These technologies are rapidly becoming essential parts of the analytical, communication, and even legal infrastructure for our societies. Despite the global proliferation of such systems, we are only just beginning to understand the flaws, limitations, and boundaries of algorithmic decision making, especially in terms of discrimination. We’re pleased to partner with Mary Kay to shine light on the potentially discriminatory impacts of using such technologies, in particular for women.”

The delivery of the initiative can be broken into three phases:

  • Phase 1: research on emerging discriminatory impacts of the use of algorithmic-decision making in the areas of employment, access to loans, and access to housing, including a focus on the impact of women as a group particularly exposed to discrimination in these contexts.
  • Phase 2: engagement with a wide-range of actors to develop advocacy strategies to call for an equality by design approach in the design, development, roll-out and monitoring of AI technologies.
  • Phase 3: engaging with international, regional and national actors to set standards mandating an equality by design approach.

The partnership with the Equal Rights Trust is just the latest initiative supported by Mary Kay in 2021 to advocate for gender equality everywhere. For nearly 60 years, Mary Kay has been committed to empowering women and their families by partnering with organizations from around the world.

ABOUT EQUAL RIGHTS TRUST

The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this mission, it works in partnership with equality defenders – civil society organizations (CSOs), lawyers, government representatives, and others committed to using law to create an equal world – providing them with the technical, strategic and practical support they need to work for the adoption and implementation of comprehensive equality laws. Since 2007, it has supported equality defenders in almost 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org

ABOUT MARY KAY

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye